Phico Therapeutics receives £2.25m grant to advance its SASPject PT4 towards clinical trials

Published: 9-Mar-2015
Research & Development Infection Control

The antibiotic is aimed at Escherichia coli and Klebsiella pneumoniae


Phico Therapeutics, a biotechnology company developing a technology for a new generation of antibiotics aimed at overcoming antibacterial resistance, has been awarded a £2.25m Translation Award by the Wellcome Trust.

The Cambridge, UK-based company will develop its SASPject PT4 antibiotic, aimed at Escherichia coli and Klebsiella pneumoniae, including multi-drug resistant strains.

The Translation Award will support product development and pre-clinical efficacy testing, together with the development of a scalable manufacturing process.

Phico Therapeutics says SASPject is a novel approach with the potential to provide a number of significant advantages over traditional antibiotics. These include a unique mode of action which makes it unlikely that the bacteria will be able to develop resistance to its antibacterial protein. It also has the ability to target any selected bacteria, including those that are multi-antibiotic resistant.

This award will enable us to advance PT4 towards clinical trials and to develop a scalable manufacturing process

K. pneumoniae and E. coli are examples of Enterobacteriaceae, a normal part of the human gut bacteria. However, in an infection, this group of bacteria can be particularly difficult to treat because they can have high levels of resistance to many antibiotics, including the so-called antibiotics of last resort, the carbapenems, giving rise to the name Carbapenem-resistant Enterobacteriaceae, or CRE. This superbug contributed to two deaths in a recent Los Angeles outbreak.

The Wellcome Trust Translation Awards aim to develop groundbreaking new technologies in the biomedical area, particularly in areas of high unmet medical need. Projects must have already demonstrated proof of principle, supported by experimental data.

Dr Heather Fairhead, Chief Executive of Phico Therapeutics, said: 'This Translation Award from the Wellcome Trust is an important validation of our SASPject technology, which we believe holds the potential to be a powerful new tool in the war against antimicrobial resistance.

'This award will enable us to advance PT4 towards clinical trials and to develop a scalable manufacturing process, and we look forward to beginning work on the project.'

  • Companies:
  • Phico Therapeutics
  • Wellcome Trust
See more

You may also like

Research & Development

Oxford clinical trial for COVID-19 treatments expands internationally

Read more
The international trial will initially focus on the treatments aspirin and colchicine, since these are readily available and affordable

Trending Articles

  1. Thermo Fisher Scientific reveals MagMax Sequential DNA/RNA Kit to advance blood cancer research The kit combines DNA and RNA isolation chemistries into a single kit, simplifying sample extraction for a broad range of downstream molecular applications
  2. Medac and chiron develop organ-on chip tech for animal free drug testing The companies aim to develop an animal-free pharmaceutical testing method that utilises organ-on chip technology, and will be used in rheumatoid arthritis drug testing
  3. Asahi Kasei Pharma grows its global portfolio with anti-CX3CR1 license The licensing deal with Chiome enhances its open innovation platform
  4. How iPSCs can bridge the translational gap in neuroscience Affecting more than one in three people, neurological disorders have a vast impact on global health while exacting a tremendous cost, reports Dr Max Mirza, Vice President of Neuroscience Drug Discovery at Sygnature Discovery
  5. RCPE and InSilicoTrials to digitalise and accelerate the development of pharmaceutical manufacturing processes RCPE and InSilicoTrials have agreed to an exclusive partnership to commercialise the XPS simulation software. Specifically developed for pharmaceutical applications, XPS allows companies to assess their process configurations in unprecedented detail and explore the decision space without time- and labour-intensive experiments

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Research & Development

Oxford clinical trial for COVID-19 treatments expands internationally

The international trial will initially focus on the treatments aspirin and colchicine, since these are readily available and affordable
Research & Development

Study demonstrates way to target hard-to-treat cancer mutation

The study was funded by Cancer Research UK and Wellcome
Research & Development

Collaborators use CRISPR to catch cancer-causing gene fusions

A team from the Wellcome Sanger Institute and collaborators have identified a new gene fusion that presents a novel drug target for multiple cancers, including brain and ovarian
Hi Tech Manufacturing

£10m research competition to tackle antimicrobial resistance

Move aims to encourage the development of innovative scientific approaches to addressing antimicrobial resistance
Research & Development

Polyphor and Wellcome Trust to develop novel antibiotics against multi-drug resistant Gram-negative pathogens

Final milestone reached ahead of schedule triggering payment of a CHF 0.97 million convertible loan amount
Research & Development

Open Data Institute tackles antibiotic resistance with Wellcome Trust grant

Pharmaceutical companies are taking steps towards openly sharing data on changes to the susceptibility of pathogens to antibiotics around the world as part of a pilot project to tackle the global problem of drug-resistant infections
Media

UK and Russian researchers join forces against AMR

Two of the key organisations, in the UK and Russia, leading efforts to combat the global problem of antimicrobial resistance (AMR) have announced a formal agreement to work together
Subscribe now